Amanda McQuade and Nathaniel Robichaud discuss how integrated proteomic and transcriptomic profiling can reveal cellular responses to genetic perturbations that are not captured through RNA analysis ...

Zongertinib in HER2-altered breast cancer: Preclinical activity and preliminary results from a phase Ia dose-escalation study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Outcomes in patients (pts) younger than 50 years old (yo) with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subanalysis of a phase 1/2 trial.

Knowing the location of a gene within intact tissue or a single cell allows scientists to unlock unknown cellular functions. This information is often lost in most genetic sequencing techniques, but ...